Ivermectin to reduce malaria transmission III. Considerations regarding regulatory and policy pathways.Ivermectin to reduce malaria transmission II. Considerations regarding clinical development pathwayIvermectin to reduce malaria transmission I. Pharmacokinetic and pharmacodynamic considerations regarding efficacy and safetyDeveloping an expanded vector control toolbox for malaria elimination.Ivermectin to reduce malaria transmission: a research agenda for a promising new tool for eliminationFalsified antimalarials: a minireview.Going beyond personal protection against mosquito bites to eliminate malaria transmission: population suppression of malaria vectors that exploit both human and animal blood.Mind the gap: residual malaria transmission, veterinary endectocides and livestock as targets for malaria vector control.Effect of ivermectin on Anopheles gambiae mosquitoes fed on humans: the potential of oral insecticides in malaria control.Oral, Slow-Release Ivermectin: Biting Back at Malaria Vectors.Cytochrome P450/ABC transporter inhibition simultaneously enhances ivermectin pharmacokinetics in the mammal host and pharmacodynamics in Anopheles gambiae.Incidental mosquitocidal effect of an ivermectin mass drug administration on Anopheles farauti conducted for scabies control in the Solomon Islands.Pilot Study of a Slow-Release Ivermectin Formulation for Malaria Control in a Pig Model.Establishment of the Ivermectin Research for Malaria Elimination Network: updating the research agenda.Travel and fake artesunate: a risky business.Combination of indoor residual spraying with long-lasting insecticide-treated nets for malaria control in Zambezia, Mozambique: a cluster randomised trial and cost-effectiveness study protocol.Targeting cattle for malaria elimination: marked reduction of Anopheles arabiensis survival for over six months using a slow-release ivermectin implant formulation.Mapping the potential use of endectocide-treated cattle to reduce malaria transmissionThe SARS-CoV-2 Ivermectin Navarra-ISGlobal Trial (SAINT) to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission in low risk, non-severe COVID-19 patients in the first 48 hours after symptoms onset: A structured summary of a study pr
P50
Q33593781-7BDF3171-60D9-4119-BD93-42437EF2D6E8Q33593846-B1F6EBC8-4CBB-4E6D-9D2A-BE72DAC8B372Q33593852-8D378900-C9E0-407C-AFD1-A04390806EBBQ33726544-7712C4A9-C26A-41C7-A98B-733B7D33F3E9Q36858823-82CF92B1-B93A-49E0-B00E-9B19BA8F8243Q38356412-7E7EEC9D-CECC-4E55-8848-01C2103C54EEQ38739434-621C646F-C19C-4A77-AF31-A631C8479987Q38936552-E4CAFCFA-57E3-4B8D-8B3C-0C830235F59FQ38936557-D0B3BD9A-1CA5-4873-8854-0C04B80548ADQ38936562-9B37F6AF-93E4-4932-80B6-D19212A0FD85Q38936568-4542B8EE-703D-44DA-BB7C-BF9711507777Q39146026-E50B896C-379A-4AE1-A2DE-B6F6E9A66A92Q42319615-5F260009-FD50-4E66-BFAE-F2B5DD37CD93Q42414575-9CE66639-4694-43D3-B545-FDCC36BC0004Q48020767-54251EFD-040E-41D4-892C-485F75222347Q51736828-6C7CD43C-CA66-4BF2-B550-A612D725B86DQ55358927-E551764E-1998-4199-B041-352A53053BDCQ64065234-6FB87309-F266-432C-A248-41B91CB94B07Q96228484-B9CB9D2F-BB0C-4D4A-8CDE-EA9E1C26C6AC
P50
description
hulumtues
@sq
investigador español
@es
onderzoeker uit Venezuela
@nl
researcher
@en
հետազոտող
@hy
name
Carlos Chaccour
@ast
Carlos Chaccour
@ca
Carlos Chaccour
@en
Carlos Chaccour
@es
Carlos Chaccour
@gl
Carlos Chaccour
@nl
Carlos Chaccour
@sl
type
label
Carlos Chaccour
@ast
Carlos Chaccour
@ca
Carlos Chaccour
@en
Carlos Chaccour
@es
Carlos Chaccour
@gl
Carlos Chaccour
@nl
Carlos Chaccour
@sl
altLabel
Carlos Chaccour Díaz
@es
Carlos J, Chaccour Díaz
@es
Carlos J, Chaccour
@es
Carlos Javier Chaccour Diaz
@es
Carlos Javier Chaccour Díaz
@es
prefLabel
Carlos Chaccour
@ast
Carlos Chaccour
@ca
Carlos Chaccour
@en
Carlos Chaccour
@es
Carlos Chaccour
@gl
Carlos Chaccour
@nl
Carlos Chaccour
@sl
P101
P1412
P69
P1053
I-4149-2018
P106
P1477
Carlos Javier Chaccour Díaz
@es
P1607
P19
P21
P31
P496
0000-0001-9812-050X
P569
1979-01-01T00:00:00Z